50% off Premium Yearly

NASDAQ:GMAB
This summary was created by AI, based on 3 opinions in the last 12 months.
Genmab ADR (GMAB) has shown mixed reviews from experts over recent months, reflecting both optimism and caution towards its performance. The company, a major player in the biotechnology sector with a focus on antibody treatments for cancer, recently reported a remarkable 19% increase in revenues, primarily driven by significant sales growth in its proprietary treatments. With a robust cash flow bolstered by a lucrative royalty agreement with Johnson & Johnson, Genmab has been strategically buying back shares, leading to increased cash reserves. Despite these positive trends, the stock has faced challenges, including a notable past decline of 14.1%, prompting some analysts to recommend cutting positions to mitigate losses. Nevertheless, there is an indication of strong long-term growth, with analysts projecting continued EPS growth exceeding 20% over the next five years, reinforcing the position of Genmab as a noteworthy long-term investment opportunity.
Genmab ADR is a American stock, trading under the symbol GMAB (previously GMAB-Q on Stockchase) on the NASDAQ (GMAB). It is usually referred to as NASDAQ:GMAB or GMAB
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on GMAB (previously GMAB-Q on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Genmab ADR.
Genmab ADR was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-02-12. Read the latest stock experts ratings for Genmab ADR.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Genmab ADR.
Genmab ADR is covered by Stockchase experts and is worth watching.
On 2026-06-15, Genmab ADR (GMAB) stock closed at a price of $24.56.
Our PAST TOP PICK with GMAB has triggered its stop at $24. To remain disciplined, we recommend covering the position at this time. Combined with our previous guidance, this will result in a net investment loss of 17%.